The biodegradable matrices of microscopic needles have been manufactured to overcome the properties of the skin barrier, which blocks the transdermal application of most active ingredients. This study shows that the different properties found in these micro-needles used in the ANTIWRINKLE FACIAL PATCHES by FACTOR SKIN 53 (length, elasticity and thickness) are optimal to guarantee the transdermal penetration of active ingredients (EFG and hyaluronic acid) and preventing the micro-needles from breaking. They also contemplated different manufacturing methods for micro-structures and ultimately concluded that the transdermal administration system using micro-needles in biodegradable patches can produce very good results.
Skin ageing is a multi-factor process that consists of two different and independent mechanisms: intrinsic and extrinsic ageing. Young skin maintains its turgor, elasticity, and flexibility, among other factors, due to its high water contents. Daily external aggressions, and the normal ageing process, result in the loss of moisture. The key molecule involved in skin humidity is hyaluronic acid (HA), which is capable of retaining water. This study shows the HA metabolism in the skin's different layers and its interactions with other components of the skin to rationally facilitate the modular capacity of dermal humidity.
In this article, Doctor Jung Dong Kim, Director of Technology at Raphas, answers questions regarding the capacities of this patch technology that uses biodegradable micro-structures ANTIWRINKLE FACIAL PATCHES by FACTOR SKIN 53. Its great advantages include ease of penetration and absolute painlessness, since it is used in the cosmetic sector and is now beginning to be used in medicine. Furthermore, he states that the technique to manufacture these micro-structures (Droplet-born air blowing, DAB) is the most innovative technique to date.
To assess the efficacy of Sirtalice™ they developed several In vivo and In vitro studies, which proved the great capacity of this ingredient to:
This In vivo study was developed on 23 middle-aged women (mean age 43 to 51 years) with crow’s feet and wrinkles in the nasolabial line before their treatment. These wrinkles were studied by means of a 3D analysis of these two areas on days 1, 5 and 10 of treatment using the biodegradable micro-structure patches and 4 weeks after applying the treatment. Comments from the subjects were also taken into consideration. Pursuant to the exhaustive analysis of the skin during and after the treatment with the patches, it was concluded that the product helps decrease wrinkles while improving the skin’s texture.
This patent presents the description of the method to manufacture the micro-structured patch that is used to administer the ingredients of FACTOR SKIN 53.
To assess the efficacy of the new Munapsys™ asset, we developed several In vivo and In vitro studies, which proved this peptide’s outstanding capacity to: